Mylan N.V. Культура компании

Ms. Heather Bresch has been the Chief Executive Officer of Mylan N.V. since January 1, 2012 and its Executive Director since March 01, 2011. Ms. Bresch served as the President of Mylan N.V. from July, 2009 to January 1, 2012 and served as its Vice President of Strategic Corporate Development from May 11, 2005 to February 2006, Chief Operating Officer and Executive Vice President from October 2007 to July 2009. Ms. Bresch was responsible for Mylan's global commercial and technical operations, strategic planning, business development and international affairs, which includes development of Mylan's antiretroviral (ARV) franchise. She oversaw the integration of Mylan's recent acquisition of Merck Generics. She has overseen the successful integration of Matrix Laboratories. She served as the Head of North American Operations of Mylan N.V. (formerly, Mylan Laboratories Inc.), a holding company of Matrix Laboratories Ltd. from January 31, 2007 to October 2, 2007. She had responsibility for Mylan's operations including Mylan Pharmaceuticals, Mylan Technologies and UDL Laboratories. She joined Mylan in 1992. She distinguished herself over her 15-year career at Mylan, including served as Senior Vice President of Strategic Corporate Development and Chief Integration Officer. She served as Vice President of Public and Government Relations at Mylan from February 2004 to April 2005, Director of Government Relations from March 2002 to February 2004 and Director of Business Development from January 2001 to March 2002. She served as the Chair of Association for Accessible Medicines (a/k/a Generic Pharmaceutical Association) since February 22, 2016. She served as the Chairman, Vice Chairman and Director of Generic Pharmaceutical Association. She serves as a Director of Association for Accessible Medicines. Ms. Bresch earned an Undergraduate degree in International Studies and Political Science from West Virginia University.

Mr. Rajiv Malik has been the President of Mylan N.V. since January 01, 2012. Mr. Malik is responsible for Mylan's operations and also oversees research and development (R&D), business development, regulatory affairs, manufacturing, quality, supply chain and medical affairs, as well as the sales and marketing of Mylan's generics business. He is responsible for helping lead Mylan's expansion into emerging and other new commercial markets, such as the commercial launch in India since 2012. Mr. Malik served important leadership positions at Mylan since January 2007. He served as Matrix's chief executive officer. Mr. Malik served as Vice President of Pharma Research and Regulatory Affairs at Ranbaxy Laboratories Ltd. Mr. Malik served as Chief Executive Officer of Mylan Laboratories Limited since February 1, 2007 and again served as Chief Executive Officer until February 28, 2008. Mr. Malik served as an Executive Vice President of Mylan Inc since October 2007. Mr. Malik served as Head of Global Technical Operations for Mylan Laboratories at Mylan Laboratories Limited and served as its Managing Director from February 1, 2007 to July 1, 2008. He served as Chief Operating Officer of Mylan N.V. from July 2009 to December 2012 and served as its Executive Vice President from October 2007 to January 1, 2012. Mr. Malik served as Head of Global Technical Operations at Mylan N.V. from January 31, 2007 to July 2009. At Mylan, Mr. Malik played a key role in significantly expanding and diversifying the global product portfolio, pipeline and manufacturing footprint. In partnership with Mylan's leadership team, he played a significant role in leading the integrations of Mylan and Matrix and Mylan and the generics business of Merck KGaA to leverage the benefits of global scale and vertical and horizontal integration. He also helped establish Mylan as a leader in antiretroviral medicines, particularly in developing markets. He has approximately 30 years of experience in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, he served as Head of Global Development and Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, where he served as Head of Generics R&D. Mr. Malik served as a Non Executive Director of Mylan Laboratories Limited since July 1, 2008. Mr. Malik has been an Executive Director of Mylan N.V. since February 11, 2013. He served as a Director of Axis Holding Pvt Ltd. He has a Master's Degree in Pharmaceutical Technology from Punjab University, India.

Mr. Anthony Mauro, also known as Tony, has been the Chief Commercial Officer at Mylan N.V. since January 4, 2016. Mr. Mauro served as and its President of North America from January 1, 2012 till February 2013. He is President of Mylan Pharmaceuticals at Mylan, Inc. from 2009 to February 2013. In his 16 years at Mylan, he has held roles of increasing responsibility, including Chief Operating Officer for Mylan Pharmaceuticals ULC in Canada, and for Mylan, Vice President of Strategic Development, North America and Vice President of Sales, North America. Mr. Mauro served as the Chairman of Association for Accessible Medicines (a/k/a Generic Pharmaceutical Association) since February 2012, served as its Vice Chairman until February 2012 and served as its Director.

Mr. Kenneth S. Parks, also known as Ken, has been Chief Financial Officer at Mylan N.V. since June 06, 2016. Mr. Parks served as the Chief Financial Officer and Senior Vice President of WESCO International Inc. since June 6, 2012 and January 01, 2014 respectively until May 31, 2016. He served as the Vice President of Finance and Chief Financial Officer of UTC Fire & Security from April 2008 to February 2012. He served as Vice President of WESCO International Inc. since June 06, 2012 until December 2013. Mr. Parks served as Vice President of Finance for the Fire & Security division at United Technologies Corporation. From 2005 to April 2008, he served as Director of Investor Relations at United Technologies Corporation. He also held several roles at UTC's Carrier Corporation division including Director, Financial Planning and Analysis (FP&A) and Vice President of Operations Finance. He spent four years in Paris as Controller and then as Director, FP&A for Carrier's European, Middle East and Africa operations. He has extensive experience working in a public company setting, including capabilities developing strong relationships with investors and financial analysts. He has more than 30 years of corporate finance experience, including responsibilities across financial planning, accounting, investor relations, treasury, tax and information technology. He began his career in public accounting with Coopers & Lybrand. Mr. Parks has held various positions within UTC and its operating units since 1990. He has been a Non Executive Director of GST Holdings Ltd. since September 9, 2009. He is a Certified Public Accountant. He earned a Bachelor of Science in Accounting from the University of Tulsa.

Ms. Deborah M. Autor has been Global Head of Quality at Mylan N.V. since 2014. Ms. Autor served as Senior Vice President of Strategic Global Quality and Regulatory Policy at Mylan N.V. from April 2013 to 2014. She served in the CDER Office of Compliance as a senior advisor and as Associate Director for Compliance Policy. Prior to joining FDA, for seven years, she represented the agency as a litigator at the U.S. Department of Justice (DOJ). She has been a Director of Parenteral Drug Association since December 2014. In recognition of her contributions to public health, she was awarded the 2011 Meritorious Executive Presidential Rank Award, the 2011 Food and Drug Law Institute's Distinguished Service and Leadership Award, and was a 2010 finalist for the prestigious Service to America Medal. Ms. Autor obtained her B.A. from Barnard College of Columbia University and her J.D. magna cum laude from Boston University School of Law, where she was an Article Editor for the Boston University Law Review.

Ms. Colleen Ostrowski serves as Senior Vice President and Treasurer at Mylan N.V. Ms. Ostrowski serves as Treasurer at Mylan Pharmaceuticals Inc. Ms. Ostrowski served as Treasurer and Vice President of ITT Corporation since August 2010. She has global operating responsibility for the treasury organization, including capital markets, pension, cash management, international treasury and risk management. She joined ITT as an Assistant Treasurer in January 2010, and has led global cash management, cash forecasting and liquidity management. Prior to joining ITT, she had a ten-year career in finance and treasury with Pfizer, Inc., culminating in the role of Senior Director, Treasury Pension Investments and Finance. She served as a Member of Pension Fund Trust at ITT. Ms. Ostrowski holds a Bachelor of Science with an emphasis in International Business from Juniata College in Huntingdon, Pa., and a Master of Business Administration degree in Finance from Penn State University.

Mr. Roger D. Graham, Jr. has been President of Mylan Specialty (a/k/a Dey Pharma, L.P.) at Mylan N.V. since June 2013. Mr. Graham served as Chief Commercial Officer of AdvanDx, Inc., since March 27, 2013. Mr. Graham served as Executive Vice President of Sales and Marketing of Auxilium Pharmaceuticals Inc. from March 2007 to November 2011. Mr. Graham served as Senior Vice President of Sales and Marketing of Adolor Corporation from April 18, 2005 to December 14, 2006. He has more than 18 years of pharmaceutical marketing and sales experience. From 2003 to 2005, Mr. Graham served as Senior Vice President of Marketing and Sales at Yamanouchi Pharma America. In addition to his work with YPA, he spent five years at Ortho-McNeil Pharmaceuticals in positions of increasing responsibility. In his role as head of the analgesia/anti- infective and urology franchise, he was responsible for a $2.2 billion franchise and led a 2200-person sales and marketing organization. In his tenure with Yamanouchi, Mr. Graham launched Vesicare, a new therapy for treating overactive bladder disease. At Ortho-McNeil Pharmaceuticals he was recognized for his leadership and work in growing market share for products that included Levaquin(R), Ditropan XL(R), Topamax(R) and Ultram(R). In addition, he has assumed a leadership position on the co-promotional teams for Vesicare, Flomax, Valtrex, Topamax, Risperdel(R) and Reminyl(R). Mr. Graham worked at the Johnson & Johnson family of companies from 1997 to 2003. From 1996 to 1997, Mr. Graham worked at Roche Laboratories. He worked at Schering Plough Corporation from 1987 to 1996. Mr. Graham is a graduate of the University of Kansas with a Bachelor's of Science degree in Business Administration and holds an M.B.A. in Finance and International Business from Seton Hall University.

Ms. Adele M. Gulfo has been an Executive Vice President of Global Collaboration and Strategic Operations at Mylan, Inc. since January 8, 2014. Ms. Gulfo is Chief Strategy Officer of Mylan N.V. since 2014. Previously, Ms. Gulfo held leadership positions at AstraZeneca Pharmaceuticals, Parke-Davis (Division of Warner-Lambert), SpectraTech Inc., and Fischer Scientific. She served as President of US Primary care business at Pfizer Inc. She served as Vice President of Healthcare Innovation and Corporate Strategy at AstraZeneca PLC. She joined Pfizer from AstraZeneca, where she served as Vice President of Business Development and Design for launch, responsible for sourcing, evaluating and securing external assets including partnerships, acquisitions and licenses, as well as clinical and commercial development across all therapeutic areas of products entering Phase IIb. She serves as Member of Industrial Advisory Board at Cleveland Clinic Innovations. She serves as Regional President, of Latin America in Pfizer's Emerging Markets Business Unit In this capacity, she leads a team of over 4,000 colleagues operating across more than 23 countries. She served as President and General Manager of Pfizer's U.S. Primary Care Business Unit, which included the managed markets (corporate and government customer) organization for all of Pfizer's Biopharmaceutical Business Units. Prior to joining Pfizer, She served as Vice President of Business Development, Innovation and Design for Launch at Astra-Zeneca Pharmaceuticals. She led the multi-billion dollar cardiovascular business, including marketed and emerging products. Among her top achievements, she grew Toprol-XL sales from $200 million to $2 billion and the launched cholesterol-lowering medicine Crestor with a significantly differentiated life-cycle development program, which enabled dramatic growth to over $2 billion in 2009 in a highly competitive market. She served positions of increasing responsibility at Warner-Lambert, including Senior Director of cardiovascular marketing. Prior to launch, She developed the market with award-winning medical and public education that helped to establish the significance of lowering cholesterol in preventing and managing heart disease. Partners included the American Heart Association, the National Institutes of Health and leading academic institutions. She is trained as a scientist with experience in both operational and strategic roles, She serves as a member of the Board of Directors for the Cleveland Clinic's Global Cardiovascular Innovation Center. Ms. Gulfo has been an Independent Director of Bemis Company, Inc. since June 23, 2015. She serves as a Director of Volunteers of America ' Greater New York, Inc. She has been awarded five U.S. Patents for innovative packaging designed to help patients adhere to their medicines. She frequently speaks at leading industry and business conferences including The Wall Street Journal's Women in the Economy: An Executive Task Force conference and has been featured in Fortune, Forbes, BusinessWeek and the Wall Street Journal. She is a member of the C200 ' the pre-eminent organization of women business leaders, the National Association of Female Executives and the Healthcare Businesswomen's Association's Advisory Board. She is especially proud of receiving the 2012 C200 Luminary Award for Corporate Entrepreneurship. Ms. Gulfo holds a bachelor's degree in Biology and Chemistry from Seton Hall University and a Master of Business Administration degree in Marketing from Fairleigh Dickinson University, both with honors. Ms. Gulfo holds post-graduate in microbiology at the University of Medicine and Dentistry of New Jersey.

Mr. Jacek Glinka has been the President of Polpharma Trade Office since January 2010. Mr. Glinka has been the President of European Business at Mylan N.V. since December 02, 2013. He served as Chief Executive Officer of the Polpharma Group from 2003 to 2006 and from 2009 to 2013. Mr. Glinka served as the President and Member of the Management Board for Polpharma S.A (formerly Zaklady Farmaceutyczne Polpharma S.A) since 2009. Since April 20, 2012, he has served as the President of the Management Board of Polfa Warszawa S.A. He served as Managing Director at Spectra Services, where he oversaw a number of acquisitions and restructurings, including the acquisition and integration of Akrihin into Polpharma Group. During his tenure, Mr. Glinka led the transformation of Polpharma from a small local player into a leading pharmaceutical company in Central and Eastern Europe. Mr. Glinka began his professional career with Delloitte & Touche in strategic consultancy department. He served as Vice President of A.T. Kearney, a strategic consultancy company. From 2004 to 2006 he served as the President of the Management Board of Polpharma SA Pharmaceutical Works and Polpharma Trade Office. Mr. Glinka served as the President of the Supervisory Board of Lubelskie Zaklady Farmaceutyczne POLFA SA and OAO Akrihin. He served as Vice President of Supervisory Board at Herbapol-Lublin SA. He served as a Member of the Supervisory Board at Medana Pharma Terpol Group SA, Zaklady Tluszczowe Kruszwica SA, Chimpharm and Spectra Investments. Since 2006, he served as a member of the Supervisory Board of Polpharma SA Pharmaceutical Works.